ClinicalTrials.gg
CompletedNCT02261259Updated Oct 20, 2026Results posted

Effects of Osteopathic Manipulative Treatment on Neuromuscular Control of the Head-neck System

An interventional study of Osteopathic manipulative treatment and No intervention in Neck Pain, sponsored by Michigan State University. Completed at 3 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Michigan State University · Not applicable, Interventional, and Basic science

How we know

Updated Oct 20, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Neck Pain with a site in United States — 21 open to participants now, 30 under way, 2 of them phase 3. Neck Pain · United States.

Enrollment
24th of 145
154 · median 60
Started
2014
with 11 others
No phase
113 of 174
14 open now
Registered
65th of 174
by date

Among the 174 studies in Neck Pain with a site in United States, this one is the 24th largest by enrollment of the 145 interventional ones that give a count, is one of 12 that started in 2014, is one of 113 with no phase, and was the 65th registered.

Neck Pain

1,367 studies on the registry are indexed under Neck Pain; 301 are open to participants now.

Browse Neck Pain studies →

Open to participants now

21 of the 174 studies in Neck Pain with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 158 Neck Pain studies recruiting now, 25 (16%) set no upper age limit and 120 (76%) stop at 75 or younger; 8 take children under 18; 27 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Neck Pain with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this project is to develop sensitive and objective clinical research tools for the assessment of head-neck motor control. In order to accomplish this goal, the investigators aim to quantify changes in head-neck motor control before and after osteopathic manipulative treatment. The investigators hypothesize that head-neck motor control will improve in neck pain participants after 4-weeks of treatment. Additionally, the investigators will compare position and force head-neck motor control between healthy controls and neck pain patients. The investigators hypothesize that baseline tests of position and force head-neck motor control will be better in healthy individuals than neck pain patients.

03

Conditions studied

  • Neck Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants must meet all of the inclusion criteria to participate in the study. Below is a list of inclusion criteria for ALL participants:

  • Age 21-65 years
  • Independently ambulatory
  • Able to speak and read English
  • Able to understand study procedures and to comply with them for the entire length of the study.

Below is an additional list of inclusion criteria for NECK PAIN participants:

  • Willing to be randomized to either immediate or delayed treatment group.
  • Musculoskeletal pain - primarily in the cervical region lasting longer than 3 months
  • Pain rating greater than or equal to 3 out of 10 as indicated on the Numeric Rating Scale for Pain
  • Neck Disability greater than or equal to 30% as indicated on the Neck Disability Index

Exclusion criteria

Exclusion Criteria:

All candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. Exclusion criteria will be self-reported. However, during each treatment session, the physicians will be watching for clinical signs and symptoms not consistent with physical findings that are suggestive of the presence of any of the exclusion criteria. In such a case, further treatment will be discontinued and the subject will be excluded.

Below is a list of exclusion criteria for ALL participants:

  • Inability or unwillingness of individual to give written .
  • Physical therapy or any other form of manual medicine (e.g., Osteopathic Manipulative Medicine, Chiropractic Manipulation, etc.), acupuncture or spinal injections within one month prior to study enrollment
  • Workers' compensation benefits in the past 3 months or ongoing medical legal issues
  • Possibly pregnant
  • Extreme obesity (>36)
  • Currently using electrical implants (e.g., cardiac pacemakers, drug delivery pumps, etc.)

History of:

  • Spinal surgery
  • Spinal fracture
  • Spinal infection (e.g., osteomyelitis)
  • Cancer

Unresolved symptoms from:

  • Head trauma
  • Inner ear infection with associated balance and coordination problems
  • Orthostatic hypotension
  • Uncontrolled hypertension
  • Vestibular disorder (e.g. vertigo)

Current diagnosis of:

  • Significant spinal deformity (e.g., scoliosis > 20 degrees, torticollis)
  • Ankylosing spondylitis
  • Spondylolisthesis grades III or IV
  • Rheumatoid arthritis
  • Osteoporosis
  • Angina or congestive heart failure symptoms
  • Active bleeding or infection in the back
  • Blindness
  • Seizures
  • Neurologic disease (e.g., Parkinson's disease, multiple sclerosis, cerebral palsy, Alzheimer's disease, amyotrophic lateral sclerosis, stroke or in the past year, cervical dystonia)

Conditions recognized by a physician any time during the study:

  • Significant or worsening signs of neurologic deficit
  • Symptoms are not consistent with mechanical findings
  • Other conditions impeding protocol implementation

Below is an additional exclusion criterion for healthy control participants:

  • Based on the minimal difference of 2 points (Childs et al., 2005), "healthy controls" with 2 points or greater pain on NRS will not be eligible to participate.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    OMT first, then No intervention

    This arm received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week), then received no intervention after for approximately 4 weeks.

    Procedure: Osteopathic manipulative treatment · Other: No intervention

  • Experimental
    No intervention, then OMT

    This arm received no intervention after for approximately 4 weeks, then received osteopathic manipulative treatment (OMT) for approximately 4 weeks (once per week).

    Procedure: Osteopathic manipulative treatment · Other: No intervention

  • No intervention
    Healthy control (no neck pain)

    In this arm, healthy controls are tested at baseline.

Interventions

  • ProcedureOsteopathic manipulative treatment

    Up to 4 sessions of osteopathic manipulative treatment (once per week)

  • OtherNo intervention

    No interventions for approximately 4 weeks

06

What researchers measure

Primary outcomes

  1. Head Position Tracking Accuracy (Flexion/Extension)

    Participants will be seated in an upright position with their upper body secured to a backrest and will wear a head harness with an attached position sensor. The angular position of the head will be displayed on a monitor 1 meter in front of the participants and they will be asked to follow a moving target by moving their head. Accuracy will be determined by taking the difference between the target position signal and the actual head position (root mean square error measured in degrees with string potentiometers).

    Time frame: Measurements from Baseline, Week 4 and Week 8

  2. Head Force Tracking Accuracy

    Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. The pad will be attached to a load cell that monitors how much force is being generated by their head. The force level will be displayed on a monitor 1 meter in front of the participants and they will be asked to follow a moving target by generating force with their head. Accuracy will be determined by taking the difference between target force signal and the actual head force (measured in Newtons with the load cell).

    Time frame: Baseline, Week 4, and Week 8

  3. Head Position Stabilization Accuracy

    Participants will be sitting upright in a seat mounted to a robotic platform (Mikrolar Hexapod Robot) with their upper body secured to a backrest and will wear a head harness with an attached position sensor. The robotic platform will provide an angular perturbation to the participant about the cervical spine in the sagittal plane while the participant is asked to maintain (stabilize) their head position in the upright posture with their eyes open. Accuracy will be determined by measuring the amount of head displacement (measured in degrees with string potentiometers) during the perturbation trial.

    Time frame: Baseline, Week 4, and Week 8

  4. Neck Force Variability

    Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. They will be asked to performed 6-seconds isometric exertions in different directions. Measured forces are converted to moments (in Newton meters), and standard deviation of the moments are reported for flexion and extension. Larger the number in the variability indicates worse performance.

    Time frame: Baseline, Week 4 (crossover), Week 8

  5. Neck Muscle Activation Directionality

    Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. They will be asked to performed 6-seconds isometric exertions in different directions. Surface EMG will be recorded from the sternocliedomastoid (SCM), splenius capitis (SPC), and upper trapezius (UT) muscles. Muscle directionality will be determined from the EMG magnitude in each direction of exertion and represented as specificity index. Specificity index ranges from 0 to 1, where 0 indicates no muscle activity and 1 indicates the highest muscle activity. Higher number indicates worst outcome.

    Time frame: Baseline, Week 4 (crossover), Week 8

Secondary outcomes

  1. Patient Reported Outcomes Measurement Information System (PROMIS)

    Assesses weekly changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with PROMIS-29 questionnaire.

    Time frame: Measurements from Baseline and Week 4 (crossover point)

  2. Change in Concomitant Medication

    Assesses weekly changes in the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.

    Time frame: Baseline, Week 4, Week 8

  3. Change in Neck Disability

    Assesses weekly changes in functional activities related to neck disability with the Neck Disability Index questionnaire.

    Time frame: Measurements from Baseline, Week 4 (crossover point), and Week 8

  4. Change in Fear Avoidance Behavior

    Assesses weekly changes in fear avoidance behavior using the Fear Avoidance Beliefs questionnaire, assessing effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).

    Time frame: Measurements from Baseline, Week 4 (crossover point), and Week 8

07

Results

Posted Oct 20, 2026

Participant flow

Participants were recruited from general population in the Greater Lansing area between June 2014 to August 2017.

Participant flow — Overall Study
MilestoneOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Started494841
Visit 1 - patient reported outcome (baseline)444340
Visit 1 - biomechanical testing (baseline)413940
Visit 2 - patient reported outcome (cross over)38370
Visit 2 - biomechanical testing (cross over)37370
Visit 3 - patient reported outcome37370
Visit 3 - biomechanical testing37370
Completed373740
Not completed12111
Withdrew: Lost to follow-up230
Withdrew: Withdrawal by subject1070
Withdrew: Changes in inclusion/exclusion criteria011

Outcome measures

PrimaryHead Position Tracking Accuracy (Flexion/Extension)

Participants will be seated in an upright position with their upper body secured to a backrest and will wear a head harness with an attached position sensor. The angular position of the head will be displayed on a monitor 1 meter in front of the participants and they will be asked to follow a moving target by moving their head. Accuracy will be determined by taking the difference between the target position signal and the actual head position (root mean square error measured in degrees with string potentiometers).

Time frame:
Measurements from Baseline, Week 4 and Week 8
Reported as:
Mean · Degrees
Head Position Tracking Accuracy (Flexion/Extension)
DegreesOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline1.2104 ± 0.06411.2306 ± 0.07461.2108 ± 0.0579
Week 41.2264 ± 0.08151.2258 ± 0.0599—
Week 81.2205 ± 0.07141.2247 ± 0.0678—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.118
PrimaryHead Force Tracking Accuracy

Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. The pad will be attached to a load cell that monitors how much force is being generated by their head. The force level will be displayed on a monitor 1 meter in front of the participants and they will be asked to follow a moving target by generating force with their head. Accuracy will be determined by taking the difference between target force signal and the actual head force (measured in Newtons with the load cell).

Time frame:
Baseline, Week 4, and Week 8
Reported as:
Mean · Newtons
Head Force Tracking Accuracy
NewtonsOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline1.2186 ± 0.07501.2601 ± 0.11871.1930 ± 0.0527
Week 41.2103 ± 0.08731.2406 ± 0.1131—
Week 81.2185 ± 0.08261.2320 ± 0.1041—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.539
PrimaryHead Position Stabilization Accuracy

Participants will be sitting upright in a seat mounted to a robotic platform (Mikrolar Hexapod Robot) with their upper body secured to a backrest and will wear a head harness with an attached position sensor. The robotic platform will provide an angular perturbation to the participant about the cervical spine in the sagittal plane while the participant is asked to maintain (stabilize) their head position in the upright posture with their eyes open. Accuracy will be determined by measuring the amount of head displacement (measured in degrees with string potentiometers) during the perturbation trial.

Time frame:
Baseline, Week 4, and Week 8
Reported as:
Mean · Degrees
Head Position Stabilization Accuracy
DegreesOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline1.5560 ± 0.49511.7926 ± 0.65421.6905 ± 0.4729
Week 41.4938 ± 0.50131.8118 ± 1.1645—
Week 81.5641 ± 0.70751.6380 ± 0.7075—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.880
PrimaryNeck Force Variability

Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. They will be asked to performed 6-seconds isometric exertions in different directions. Measured forces are converted to moments (in Newton meters), and standard deviation of the moments are reported for flexion and extension. Larger the number in the variability indicates worse performance.

Time frame:
Baseline, Week 4 (crossover), Week 8
Reported as:
Mean · Nm
Neck Force Variability
NmOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline - Flexion Force Variability0.1513 ± 0.08840.2530 ± 0.37180.1593 ± 0.0831
Week 4 - Flexion Force Variability0.1396 ± 0.07060.1920 ± 0.1470—
Baseline - Extension Force Variability0.1382 ± 0.12750.2932 ± 0.67750.1255 ± 0.0532
Week 4 - Extension Force Variability0.1309 ± 0.12420.1746 ± 0.2135—
Week 8 - Extension Force Variability0.1391 ± 0.16760.1254 ± 0.0726—
Week 8 - Flexion Force Variability0.1307 ± 0.05570.1435 ± 0.0674—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.075
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.278
PrimaryNeck Muscle Activation Directionality

Participants will be seated in an upright position with their upper body secured to a backrest and will be asked to generate force with their head against a fixed pad. They will be asked to performed 6-seconds isometric exertions in different directions. Surface EMG will be recorded from the sternocliedomastoid (SCM), splenius capitis (SPC), and upper trapezius (UT) muscles. Muscle directionality will be determined from the EMG magnitude in each direction of exertion and represented as specificity index. Specificity index ranges from 0 to 1, where 0 indicates no muscle activity and 1 indicates the highest muscle activity. Higher number indicates worst outcome.

Time frame:
Baseline, Week 4 (crossover), Week 8
Reported as:
Mean · Units on a scale
Neck Muscle Activation Directionality
Units on a scaleOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline - Right SCM specificity index0.3863 ± 0.15560.4476 ± 0.14020.4786 ± 0.1520
Week 4 - Right SCM specificity index0.4211 ± 0.13870.4366 ± 0.1316—
Week 8 - Right SCM specificity index0.3995 ± 0.14710.4503 ± 0.1347—
Baseline - Right SPC specificity index0.3327 ± 0.12360.2979 ± 0.11080.3434 ± 0.1083
Week 4 - Right SPC specificity index0.3408 ± 0.15890.2899 ± 0.0972—
Week 8 - Right SPC specificity index0.3685 ± 0.13680.2724 ± 0.1091—
Baseline - Right UT specificity index0.1877 ± 0.13940.1994 ± 0.13880.1906 ± 0.1268
Week 4- Right UT specificity index0.2094 ± 0.17080.2166 ± 0.1519—
Week 8 - Right UT specificity index0.2188 ± 0.13560.2198 ± 0.1577—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.297
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.235
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.985
SecondaryPatient Reported Outcomes Measurement Information System (PROMIS)

Assesses weekly changes in physical function, anxiety, depression, fatigue, sleep, satisfaction with social role, and pain with PROMIS-29 questionnaire.

Time frame:
Measurements from Baseline and Week 4 (crossover point)
Reported as:
Least squares mean · t-score
Patient Reported Outcomes Measurement Information System (PROMIS)
t-scoreOsteopathic Manipulative Treatment (OMT)No Intervention
Pain interference - Week 457.04 ± 0.8456.97 ± 0.85
Satisfaction with participation in social roles - Week 445.58 ± 1.0046.76 ± 1.01
Sleep disturbance - Week 453.11 ± 0.9556.36 ± 0.96
Fatigue - Week 454.09 ± 0.9757.35 ± 0.99
Depression - Week 447.33 ± 0.7549.92 ± 0.76
Anxiety - Week 449.23 ± 0.9950.54 ± 1.00
Physical function - Week 445.75 ± 0.7844.40 ± 0.79
Statistical analysis
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.950
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.408
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.003
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.022
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.018
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.358
  • Osteopathic Manipulative Treatment (OMT) vs No Intervention · ANCOVA · p = 0.228
SecondaryChange in Concomitant Medication

Assesses weekly changes in the use of medication with a questionnaire. Patients were asked to report medications used within the past 7 days.

Time frame:
Baseline, Week 4, Week 8
Reported as:
Mean · Number of medication
Change in Concomitant Medication
Number of medicationOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline2.2 ± 2.61.9 ± 2.60.7 ± 1.1
Week 42.1 ± 2.22.2 ± 2.8—
Week 81.7 ± 2.42.1 ± 2.8—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.3183
SecondaryChange in Neck Disability

Assesses weekly changes in functional activities related to neck disability with the Neck Disability Index questionnaire.

Time frame:
Measurements from Baseline, Week 4 (crossover point), and Week 8
Reported as:
Mean · % (out of 50)
Change in Neck Disability
% (out of 50)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
Baseline34.6 ± 9.737.5 ± 9.11.9 ± 3.2
Week 429.3 ± 11.736.5 ± 9.6—
Week 830.5 ± 12.130.9 ± 12.6—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.010
SecondaryChange in Fear Avoidance Behavior

Assesses weekly changes in fear avoidance behavior using the Fear Avoidance Beliefs questionnaire, assessing effects of fear-avoidance beliefs about physical activity and work. Patients rated statements on a scale from 0 (completely disagree) to 6 (completely agree). Scores are then summed for each category: "Physical activity" (total of 4 statements, ranges from 0 to 24), and "Work" (total of 7 statements ranges from 0 to 42). Higher scores indicate stronger fear-avoidance belief (i.e. worse outcome).

Time frame:
Measurements from Baseline, Week 4 (crossover point), and Week 8
Reported as:
Mean · scores on a scale
Change in Fear Avoidance Behavior
scores on a scaleOMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)
FABQ Work- Baseline13.32 ± 7.9114.65 ± 9.104.28 ± 8.31
FABQ Work- Week 412.92 ± 9.4313.92 ± 7.92—
FABQ Work- Week 811.92 ± 8.1014.97 ± 9.40—
FABQ Physical Activity - Baseline11.89 ± 5.6212.49 ± 4.482.38 ± 4.27
FABQ Physical Activity - Week 411.41 ± 5.4912.30 ± 5.00—
FABQ Physical Activity - Week 811.00 ± 5.5511.68 ± 5.50—
Statistical analysis
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.896
  • OMT First, Then No Intervention vs No Intervention, Then OMT · ANCOVA · p = 0.593

Adverse events

Collected over Baseline-Week 8. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Osteopathic Manipulative Treatment (OMT)0/86 (0%)0/86 (0%)46/86 (53.5%)
No Intervention0/86 (0%)0/86 (0%)32/86 (37.2%)
Healthy Control (no Neck Pain)0/40 (0%)0/40 (0%)8/40 (20%)
Most frequent other events
Most frequent other events
EventOsteopathic Manipulative Treatment (OMT)No InterventionHealthy Control (no Neck Pain)
Neck painMusculoskeletal and connective tissue disorders24/8613/863/40
MyalgiaMusculoskeletal and connective tissue disorders19/8610/864/40
Muscle fatigueMusculoskeletal and connective tissue disorders14/867/861/40
Back painMusculoskeletal and connective tissue disorders8/861/860/40
ColdRespiratory, thoracic and mediastinal disorders6/864/860/40
HeadahceNervous system disorders6/865/860/40

Baseline characteristics

Number of participants who were randomized, including participants who dropped out prior to the baseline (Visit 1) measurement.

Age, Categorical
Age, Categorical(Participants)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
<=18 years0000
Between 18 and 65 years434338124
>=65 years1023
Sex: Female, Male
Sex: Female, Male(Participants)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
Female33332187
Male11101940
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
American Indian or Alaska Native1102
Asian4138
Native Hawaiian or Other Pacific Islander0011
Black or African American1326
White363632104
More than one race2204
Unknown or Not Reported0022
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
Hispanic or Latino72413
Not Hispanic or Latino373934110
Unknown or Not Reported0224
Region of Enrollment
Region of Enrollment(participants)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
United States494841138
Average pain
Average pain(units on a scale)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
Mean5.52 ± 1.365.28 ± 1.74.13 ± .333.74 ± 2.78
Neck Disability Index (NDI)
Neck Disability Index (NDI)(%)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
Mean35.8 ± 9.937.4 ± 8.91.9 ± 3.225.7 ± 1.8
Fear Avoidance Belief Questionnaire (FABQ)
Fear Avoidance Belief Questionnaire (FABQ)(units on a scale)OMT First, Then No InterventionNo Intervention, Then OMTHealthy Control (no Neck Pain)Total
Work (out of 42)13.84 ± 8.3214.67 ± 8.834.28 ± 8.3111.11 ± 9.63
Physical Activity (out of 24)12.02 ± 5.8012.44 ± 4.172.38 ± 4.279.27 ± 6.60

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • MSU Osteopathic Manual Medicine
    East Lansing, Michigan 48823, United States
  • MSU Musculoskeletal Rehabilitation
    Lansing, Michigan 48891, United States
  • Michigan State University Center for Orthopedic Research
    Lansing, Michigan 48910, United States
09

References and documents

Publications

  • Reeves NP, Popovich JM Jr, Priess MC, Cholewicki J, Choi J, Radcliffe CJ. Reliability of assessing trunk motor control using position and force tracking and stabilization tasks. J Biomech. 2014 Jan 3;47(1):44-9. doi: 10.1016/j.jbiomech.2013.10.018. Epub 2013 Oct 22. PubMed 24262851 ↗
  • Popovich JM Jr, Reeves NP, Priess MC, Cholewicki J, Choi J, Radcliffe CJ. Quantitative measures of sagittal plane head-neck control: a test-retest reliability study. J Biomech. 2015 Feb 5;48(3):549-54. doi: 10.1016/j.jbiomech.2014.11.023. Epub 2014 Nov 27. PubMed 25553673 ↗
  • Ramadan A, Choi J, Cholewicki J, Reeves NP, Popovich JM, Radcliffe CJ. Feasibility of Incorporating Test-Retest Reliability and Model Diversity in Identification of Key Neuromuscular Pathways During Head Position Tracking. IEEE Trans Neural Syst Rehabil Eng. 2019 Feb;27(2):275-282. doi: 10.1109/TNSRE.2019.2891525. Epub 2019 Jan 10. PubMed 30629508 ↗
  • Ramadan A, Boss C, Choi J, Peter Reeves N, Cholewicki J, Popovich JM Jr, Radcliffe CJ. Selecting Sensitive Parameter Subsets in Dynamical Models With Application to Biomechanical System Identification. J Biomech Eng. 2018 Jul 1;140(7):0745031-8. doi: 10.1115/1.4039677. PubMed 29570752 ↗
  • Cholewicki J, Popovich JM Jr, Reeves NP, DeStefano LA, Rowan JJ, Francisco TJ, Prokop LL, Zatkin MA, Lee AS, Sikorskii A, Pathak PK, Choi J, Radcliffe CJ, Ramadan A. The effects of osteopathic manipulative treatment on pain and disability in patients with chronic neck pain: A single-blinded randomized controlled trial. PM R. 2022 Dec;14(12):1417-1429. doi: 10.1002/pmrj.12732. Epub 2022 Jan 18. PubMed 34719122 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Nov 2017, 40 months.

Results were first posted in Oct 2026, 8 years 11 months after primary completion.

Of 768 non-industry interventional studies with no phase under Neck Pain, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 15. This study's 40 months is above that.

Counting every sponsor, half of 777 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2014
First posted
Oct 10, 2014
StartActual
Jun 26, 2014
Primary completionActual
Nov 13, 2017
CompletionActual
Nov 13, 2017
Results first posted
Oct 20, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 20, 2026
Start date
Jun 1, 2014→Jun 26, 2014
Oct 20, 2026
Interventions
Added No intervention. Arms added: OMT first, then No intervention·No intervention, then OMT; arms removed: Immediate treatment·Delayed treatment
Oct 20, 2026
Primary outcomes
1 edited, 4 added, 4 removed
What changed in the outcomes
  • ChangedBefore Change from baseline to week 4 and from week 4 to 8 in head force tracking accuracyNow Head Force Tracking AccuracyTime frame: Change from baseline to week 4 and from week 4 to 8 → Baseline, Week 4, and Week 8
  • AddedHead Position Tracking Accuracy (Flexion/Extension)Time frame: Measurements from Baseline, Week 4 and Week 8
  • AddedHead Position Stabilization AccuracyTime frame: Baseline, Week 4, and Week 8
  • AddedNeck Force VariabilityTime frame: Baseline, Week 4 (crossover), Week 8
  • AddedNeck Muscle Activation DirectionalityTime frame: Baseline, Week 4 (crossover), Week 8
  • RemovedChange from baseline to week 4 and from week 4 to 8 in head position tracking accuracyTime frame: Change from baseline to week 4 and from week 4 to 8
  • RemovedChange from baseline to week 4 and from week 4 to 8 in head position stabilization accuracyTime frame: Change from baseline to week 4 and from week 4 to 8
  • RemovedChange from baseline to week 4 in neck force and muscle activation directionalityTime frame: Change from baseline to week 4
  • RemovedChange from week 4 to 8 in neck force and muscle activation directionalityTime frame: Change from week 4 to 8
Oct 20, 2026
Documents
Publications
Results publication added: Cholewicki J, Popovich JM Jr, Reeves NP, DeStefano LA, Rowan JJ, Francisco TJ, Prokop LL, Zatkin MA, Lee AS, Sikorskii A, Pathak PK, Choi J, Radcliffe CJ, Rama… PubMed 34719122 ↗
Oct 20, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedChange in Patient Reported Outcomes Measurement Information System (PROMIS)Time frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline and Week 4 (crossover point)
  • EditedChange in concomitant medicationConcomitant MedicationTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4, Week 8
  • EditedChange in neck disabilityNeck DisabilityTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline, Week 4 (crossover point), and Week 8
  • EditedChange in fear avoidance behaviorFear Avoidance BehaviorTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline, Week 4 (crossover point), and Week 8
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Results posted
    Publications Results publication added: Cholewicki J, Popovich JM Jr, Reeves NP, DeStefano LA, Rowan JJ, Francisco TJ, Prokop LL, Zatkin MA, Lee AS, Sikorskii A, Pathak PK, Choi J, Radcliffe CJ, Rama… PubMed 34719122 ↗
    Start date Jun 1, 2014→Jun 26, 2014
    Primary outcomes 1 edited, 4 added, 4 removed
    What changed in the outcomes
    • ChangedBefore Change from baseline to week 4 and from week 4 to 8 in head force tracking accuracyNow Head Force Tracking AccuracyTime frame: Change from baseline to week 4 and from week 4 to 8 → Baseline, Week 4, and Week 8
    • AddedHead Position Tracking Accuracy (Flexion/Extension)Time frame: Measurements from Baseline, Week 4 and Week 8
    • AddedHead Position Stabilization AccuracyTime frame: Baseline, Week 4, and Week 8
    • AddedNeck Force VariabilityTime frame: Baseline, Week 4 (crossover), Week 8
    • AddedNeck Muscle Activation DirectionalityTime frame: Baseline, Week 4 (crossover), Week 8
    • RemovedChange from baseline to week 4 and from week 4 to 8 in head position tracking accuracyTime frame: Change from baseline to week 4 and from week 4 to 8
    • RemovedChange from baseline to week 4 and from week 4 to 8 in head position stabilization accuracyTime frame: Change from baseline to week 4 and from week 4 to 8
    • RemovedChange from baseline to week 4 in neck force and muscle activation directionalityTime frame: Change from baseline to week 4
    • RemovedChange from week 4 to 8 in neck force and muscle activation directionalityTime frame: Change from week 4 to 8
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedChange in Patient Reported Outcomes Measurement Information System (PROMIS)Time frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline and Week 4 (crossover point)
    • EditedChange in concomitant medicationConcomitant MedicationTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Baseline, Week 4, Week 8
    • EditedChange in neck disabilityNeck DisabilityTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline, Week 4 (crossover point), and Week 8
    • EditedChange in fear avoidance behaviorFear Avoidance BehaviorTime frame: The expected average is weekly for this outcome measure until the end (expected average of 8 weeks). → Measurements from Baseline, Week 4 (crossover point), and Week 8
    Interventions Added No intervention. Arms added: OMT first, then No intervention·No intervention, then OMT; arms removed: Immediate treatment·Delayed treatment
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02261259
Responsible party
Jacek Cholewicki (Walter F. Patenge Professor, Michigan State University) — Principal investigator
First posted
Oct 10, 2014
Start date
Jun 26, 2014
Primary completion
Nov 13, 2017
Completion
Nov 13, 2017
Results posted
Oct 20, 2026
Last update
Oct 20, 2026

Study contacts

Jacek Cholewicki, PhD
principal investigator · Michigan State University
Norman P Reeves, PhD
principal investigator · Michigan State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion